Personalized medicine startup files for $100M initial public offering, but analyst says move could be prelude to an acquisition by a major life sciences company.
|
Neulasta and Neupogen may increase leukemia risk, but investors are doubtful.
|
Biotech giant hangs tough, but faces questions about over-prescriptions and rival Roche.
|
Gilead Sciences licenses AIDS treatment Tenofovir to eight more Indian companies.
|
U.S. ships in Asia will have labs to quickly detect bird flu.
|
GlaxoSmithKline shows high response at low doses of its avian flu inoculation.
|
Roche puts brakes on Avastin trial; Barr buys PLIVA for $2.2B; Cyberonics gets a subpoena.
|
The nanotech startup plans to bring a disease-diagnostic system to the market.
|
The drugmaker says its WHO donation of 3 million Tamiflu courses is ready.
|
Lymphoma drug from Genentech, Biogen, and Roche OK'd for rheumatoid arthritis.
|
Swiss drug maker files for authorization to market early-stage breast cancer treatment with European Medicines Agency.
|
Pharmaceutical company giants Roche and Genentech suspend recruitment for trials of their colon cancer drug Avastin after patients die.
|
Biopharma firm Innogenetics settles testing kit patent suit with Third Wave Technologies.
|
A study with monkeys suggests Gilead’s HIV treatment might prevent spread of the virus.
|
World’s biggest biotech firm announces huge investment in manufacturing and R&D.
|
Drug maker disputes medical paper doubting bird flu treatment’s effectiveness.
|
BioCryst receives expedited review of its peramivir injection for flu treatments.
|
Less stringent regulations in Asian nations reduce the timeline for drug discovery.
|
As Asian countries plan for a pandemic flu outbreak, some scientists wonder if they’re looking at the right virus.
|
Roche grants sublicense to Hetero Drugs to increase production of avian flu treatment.
|
Page
1
of
3
|